188 related articles for article (PubMed ID: 19421321)
1. Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial.
Mok E; Letellier G; Cuisset JM; Denjean A; Gottrand F; Alberti C; Hankard R
PLoS One; 2009; 4(5):e5448. PubMed ID: 19421321
[TBL] [Abstract][Full Text] [Related]
2. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy.
Tarnopolsky MA; Mahoney DJ; Vajsar J; Rodriguez C; Doherty TJ; Roy BD; Biggar D
Neurology; 2004 May; 62(10):1771-7. PubMed ID: 15159476
[TBL] [Abstract][Full Text] [Related]
3. Effect of glutamine on glucose metabolism in children with Duchenne muscular dystrophy.
Letellier G; Mok E; Alberti C; De Luca A; Gottrand F; Cuisset JM; Denjean A; Darmaun D; Hankard R
Clin Nutr; 2013 Jun; 32(3):386-90. PubMed ID: 23021433
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
[TBL] [Abstract][Full Text] [Related]
5. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
[TBL] [Abstract][Full Text] [Related]
6. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.
Escolar DM; Buyse G; Henricson E; Leshner R; Florence J; Mayhew J; Tesi-Rocha C; Gorni K; Pasquali L; Patel KM; McCarter R; Huang J; Mayhew T; Bertorini T; Carlo J; Connolly AM; Clemens PR; Goemans N; Iannaccone ST; Igarashi M; Nevo Y; Pestronk A; Subramony SH; Vedanarayanan VV; Wessel H;
Ann Neurol; 2005 Jul; 58(1):151-5. PubMed ID: 15984021
[TBL] [Abstract][Full Text] [Related]
7. Evidence of muscle loss delay and improvement of hyperinsulinemia and insulin resistance in Duchenne muscular dystrophy supplemented with omega-3 fatty acids: A randomized study.
Rodríguez-Cruz M; Atilano-Miguel S; Barbosa-Cortés L; Bernabé-García M; Almeida-Becerril T; Cárdenas-Conejo A; Del Rocío Cruz-Guzmán O; Maldonado-Hernández J
Clin Nutr; 2019 Oct; 38(5):2087-2097. PubMed ID: 30420291
[TBL] [Abstract][Full Text] [Related]
8. Effect of a multicomponent nutritional supplement on functional outcomes for Duchenne muscular dystrophy: A randomized controlled trial.
Davidson ZE; Hughes I; Ryan MM; Kornberg AJ; Cairns AG; Jones K; Hutchence M; Sampaio H; Morrison M; Truby H
Clin Nutr; 2021 Jul; 40(7):4702-4711. PubMed ID: 34237697
[TBL] [Abstract][Full Text] [Related]
9. Oral glutamine and amino acid supplementation inhibit whole-body protein degradation in children with Duchenne muscular dystrophy.
Mok E; Eléouet-Da Violante C; Daubrosse C; Gottrand F; Rigal O; Fontan JE; Cuisset JM; Guilhot J; Hankard R
Am J Clin Nutr; 2006 Apr; 83(4):823-8. PubMed ID: 16600934
[TBL] [Abstract][Full Text] [Related]
10. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.
Campbell C; McMillan HJ; Mah JK; Tarnopolsky M; Selby K; McClure T; Wilson DM; Sherman ML; Escolar D; Attie KM
Muscle Nerve; 2017 Apr; 55(4):458-464. PubMed ID: 27462804
[TBL] [Abstract][Full Text] [Related]
11. Effect of Combination l-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Hafner P; Bonati U; Klein A; Rubino D; Gocheva V; Schmidt S; Schroeder J; Bernert G; Laugel V; Steinlin M; Capone A; Gloor M; Bieri O; Hemkens LG; Speich B; Zumbrunn T; Gueven N; Fischer D
JAMA Netw Open; 2019 Oct; 2(10):e1914171. PubMed ID: 31664444
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
[TBL] [Abstract][Full Text] [Related]
14. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
[TBL] [Abstract][Full Text] [Related]
15. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
Dittrich S; Graf E; Trollmann R; Neudorf U; Schara U; Heilmann A; von der Hagen M; Stiller B; Kirschner J; Pozza RD; Müller-Felber W; Weiss K; von Au K; Khalil M; Motz R; Korenke C; Lange M; Wilichowski E; Pattathu J; Ebinger F; Wiechmann N; Schröder R;
Orphanet J Rare Dis; 2019 May; 14(1):105. PubMed ID: 31077250
[TBL] [Abstract][Full Text] [Related]
16. Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study.
Banerjee B; Sharma U; Balasubramanian K; Kalaivani M; Kalra V; Jagannathan NR
Magn Reson Imaging; 2010 Jun; 28(5):698-707. PubMed ID: 20395096
[TBL] [Abstract][Full Text] [Related]
17. Profoundly lower muscle mass and rate of contractile protein synthesis in boys with Duchenne muscular dystrophy.
Evans WJ; Shankaran M; Smith EC; Morris C; Nyangau E; Bizieff A; Matthews M; Mohamed H; Hellerstein M
J Physiol; 2021 Dec; 599(23):5215-5227. PubMed ID: 34569076
[TBL] [Abstract][Full Text] [Related]
18. Potential therapeutic impact of omega-3 long chain-polyunsaturated fatty acids on inflammation markers in Duchenne muscular dystrophy: A double-blind, controlled randomized trial.
Rodríguez-Cruz M; Cruz-Guzmán ODR; Almeida-Becerril T; Solís-Serna AD; Atilano-Miguel S; Sánchez-González JR; Barbosa-Cortés L; Ruíz-Cruz ED; Huicochea JC; Cárdenas-Conejo A; Escobar-Cedillo RE; Yam-Ontiveros CA; Ricárdez-Marcial EF
Clin Nutr; 2018 Dec; 37(6 Pt A):1840-1851. PubMed ID: 28987470
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
[TBL] [Abstract][Full Text] [Related]
20. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.
Victor RG; Sweeney HL; Finkel R; McDonald CM; Byrne B; Eagle M; Goemans N; Vandenborne K; Dubrovsky AL; Topaloglu H; Miceli MC; Furlong P; Landry J; Elashoff R; Cox D;
Neurology; 2017 Oct; 89(17):1811-1820. PubMed ID: 28972192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
